Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Merck
McKesson
Mallinckrodt
Express Scripts

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 204640

See Plans and Pricing

« Back to Dashboard

NDA 204640 describes ADRENALIN, which is a drug marketed by Par Sterile Products and is included in two NDAs. It is available from seven suppliers. There are three patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ADRENALIN profile page.

The generic ingredient in ADRENALIN is epinephrine. There are twenty-one drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the epinephrine profile page.
Summary for 204640
Tradename:ADRENALIN
Applicant:Par Sterile Products
Ingredient:epinephrine
Patents:3
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 204640
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ADRENALIN epinephrine SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 204640 NDA Par Pharmaceutical, Inc. 42023-168 42023-168-01 1 VIAL in 1 CARTON (42023-168-01) > 30 mL in 1 VIAL
ADRENALIN epinephrine SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS 204640 NDA HF Acquisition Co LLC, DBA HealthFirst 51662-1307 51662-1307-1 1 VIAL, MULTI-DOSE in 1 CARTON (51662-1307-1) > 30 mL in 1 VIAL, MULTI-DOSE
Paragraph IV (Patent) Challenges for 204640
Tradename Dosage Ingredient NDA Submissiondate
ADRENALIN SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS epinephrine 204640 2018-08-20

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUSStrengthEQ 30MG BASE/30ML (EQ 1MG BASE/ML)
Approval Date:Dec 18, 2013TE:RLD:Yes
Patent:  Start TrialPatent Expiration:Mar 13, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Mar 13, 2035Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Mar 13, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Moodys
Merck
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.